Close Menu

restructuring

According to the company, it is responding to "mounting cost pressures in healthcare" and to "increasing hurdles for the approval and pricing of new medicines."

The firm's Pharmaceutical Divisions will be primarily affected by the job cuts and transfers. The program is expected to result in annual cost savings of CHF2.4 billion ($2.4 billion) for Roche.

The firm's lab services revenues were hurt by lower sample volume, but were partially offset by a higher average price per sample. Celera also announced a restructuring program intended to cut costs by $10 million next year.

The firm hopes to cut its monthly burn rate 32 percent as it pushes forward with plans to launch second-generation miRview tests.

The firm will cut another 14 positions, on top of the previously announced 40 jobs, as it aims to reduce its operating costs.

A streamlining of its Life Sciences and Clinical Labs operations is expected to result in a reduction of annualized operating expenditures of $4 million.

As the firm completes the first phase of its restructuring, it reported a 51 percent increase in revenues and appointed a new CEO.

The firm expects to incur approximately $667,000 in restructuring costs.

The firm has decided to focus on growing its molecular diagnostics services business rather than continuing to pursue a deal with a partner.

The firm is pressing ahead with its plans to focus on the molecular diagnostics market. Part of its restructuring includes the departure of J. William Efcavitch as chief technology officer.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.